- Home
- CAPN vs MURA Comparison
CAPN vs MURA Comparison
Compare CAPN & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPN
- MURA
- Stock Information
- Founded
- CAPN 2024
- MURA 2013
- Country
- CAPN United States
- MURA Ireland
- Employees
- CAPN N/A
- MURA N/A
- Industry
- CAPN
- MURA
- Sector
- CAPN
- MURA
- Exchange
- CAPN NYSE
- MURA Nasdaq
- Market Cap
- CAPN 78.7M
- MURA 67.4M
- IPO Year
- CAPN 2024
- MURA N/A
- Fundamental
- Price
- CAPN $10.11
- MURA $4.05
- Analyst Decision
- CAPN
- MURA Strong Buy
- Analyst Count
- CAPN 0
- MURA 5
- Target Price
- CAPN N/A
- MURA $16.00
- AVG Volume (30 Days)
- CAPN 460.0
- MURA 135.3K
- Earning Date
- CAPN 01-01-0001
- MURA 03-25-2025
- Dividend Yield
- CAPN N/A
- MURA N/A
- EPS Growth
- CAPN N/A
- MURA N/A
- EPS
- CAPN N/A
- MURA N/A
- Revenue
- CAPN N/A
- MURA N/A
- Revenue This Year
- CAPN N/A
- MURA N/A
- Revenue Next Year
- CAPN N/A
- MURA N/A
- P/E Ratio
- CAPN N/A
- MURA N/A
- Revenue Growth
- CAPN N/A
- MURA N/A
- 52 Week Low
- CAPN $10.00
- MURA $2.87
- 52 Week High
- CAPN $10.60
- MURA $5.62
- Technical
- Relative Strength Index (RSI)
- CAPN N/A
- MURA 51.01
- Support Level
- CAPN N/A
- MURA $4.13
- Resistance Level
- CAPN N/A
- MURA $4.39
- Average True Range (ATR)
- CAPN 0.00
- MURA 0.25
- MACD
- CAPN 0.00
- MURA -0.02
- Stochastic Oscillator
- CAPN 0.00
- MURA 42.50
About CAPN CAYSON ACQUISITION CORP
Cayson Acquisition Corp is a blank check company.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.